Objective-Leptin promotes atherosclerosis and vessel wall remodeling. As abdominal aortic aneurysm (AAA) formation involves tissue remodeling, we hypothesized that local leptin synthesis initiates and promotes this process. Methods and Results-Human surgical AAA walls were analyzed for antigen and mRNA levels of leptin and leptin receptor, as well as mRNA for matrix metalloproteinases (MMP)-9 and MMP-12. Leptin and leptin receptor antigen were evident in all AAAs, and leptin, MMP-9, and MMP-12 mRNA was increased relative to age-matched nondilated controls. To simulate in vivo local leptin synthesis, ApoE -/mice were subjected to a paravisceral periaortic application of low-dose leptin. Leptin-treated aortas exhibited decreased transforming growth factor-β and increased MMP-9 mRNA levels 5 days after surgery, and leptin receptor mRNA was upregulated by day 28. Serial ultrasonography demonstrated accelerated regional aortic diameter growth after 28 days, correlating with local medial degeneration, increased MMP-9, MMP-12, and periadventitial macrophage clustering. Furthermore, the combination of local periaortic leptin and systemic angiotensin II administration augmented medial MMP-9 synthesis and aortic aneurysm size. Conclusion-Leptin is locally synthesized in human AAA wall. Paravisceral aortic leptin in ApoE -/mice induces local medial degeneration and augments angiotensin II-induced AAA, thus suggesting novel mechanistic links between leptin and AAA formation. (Arterioscler Thromb Vasc Biol. 2013;33:311-320.) Key Words: abdominal aortic aneurysm ◼ angiotensin II ◼ leptin ◼ transforming growth factor-β ◼ vessel wall remodeling
A bdominal aortic aneurysm (AAA) is an age-related degenerative disease of the aortic wall, affecting ≈5% of all men aged >65 years. 1, 2 It involves life-threatening morbidity and has been listed as the 13th leading cause of death in the United States, 3 where it imposes a heavy financial burden on healthcare systems. 4 Several cardiovascular risk factors have been identified for AAA, including atherosclerosis, old age, male sex hypertension, genetic predilection, and smoking. 5 Notably, cessation of smoking has recently been shown to lead to a marked reduction in the prevalence of AAA. 6 Basic and clinical studies have revealed multiple complex mechanisms that participate in AAA pathogenesis. These include clustering of adventitial and medial inflammatory infiltrates, synthesis and activation of proteolytic enzymes like matrix metalloproteinases (MMPs) or cysteine proteases, and pathological angiogenesis. [7] [8] [9] Insights into mechanisms have been mainly derived from the pathological analysis of human AAA tissues and mouse models designed to rapidly elicit an AAA. Human surgical tissue and experimentally induced AAAs in mice, however, usually represent an advanced stage of aortic degeneration. Furthermore, current murine AAA models involve aggressive and nonphysiological stimuli to achieve rapid AAA formation. Models currently in use involve excessive proteolytic activity in conjunction with forceful expansion of the abdominal aortic wall as in the elastase model 10 or corrosive agents such as CaCl 2 to induce elastin degeneration and calcification. 11 The classically accepted angiotensin II (Ang II) AAA model also involves major systemic perturbation of normal mouse physiology. 12, 13 Therefore, current animal models may not reflect the true pathogenesis of human AAA, leaving the precise identity of the early initiators of the disease still enigmatic.
Clinical studies exploring biomarkers for the development of AAA have demonstrated that measures of obesity are independently associated with AAA. Among the adipokines, serum level of resistin, originating mainly from monocytesmacrophages, have been shown to correlate with AAA. 14 Despite its ability to modulate vascular smooth muscle cells (SMCs) and endothelial function in vitro, resistin has yet to February 2013 be implicated in the process of AAA pathogenesis. We have focused our investigation on a different adipokine, leptin, a regulatory hormone known to participate in vital endocrine and immune functions. 15 Leptin plays a key role in experimentally induced atherogenesis 16, 17 and is used as a clinical biomarker of symptomatic cardiovascular diseases, related to coronary artery occlusion 18 or hemorrhagic stroke. 19 The leptin hormone is capable of activating multiple processes associated with extracellular matrix (ECM) degradation and arterial vessel wall remodeling, in response to vascular injury in obese mice. 20 The effects attributed to leptin may be related to induction of reactive oxygen radicals, 21 enhanced expression of intracellular adhesive molecules and monocyte chemotactic protein-1, 22 and induced chemotaxis on monocytes. 23 It is therefore not surprising that macrophages have been found to cluster in the aortic adventitia and perivascular space, where they likely promote regional synthesis of cytokines and MMPs. 24 Additionally, the chymase enzyme, released from degranulating mast cells after interaction with leptin, stimulates monocytes to synthesize matrix-degrading MMPs and activates MMP-9. 25 The interaction between mast cells and leptin may also induce medial SMC apoptosis and vessel wall remodeling by proinflammatory cytokines interleukin-6 and interferon-γ. 26 Leptin also promotes vascular endothelial growth factor-A synthesis, resulting in neovascularization as demonstrated in human and mouse AAAs, in which the latter process has been shown to play a detrimental role in the development of murine AAA. 27 We have recently demonstrated local induction of leptin synthesis in human carotid atherosclerotic plaques, presumably driven by tumor necrosis factor-α. Levels of leptin mRNA in the plaque correlated with lesion instability, suggesting a role for leptin in plaque remodeling. 28 In pursuit of vascular systems that might similarly undergo long-term remodeling processes, we postulated that leptin may play a role in early mechanisms of AAA pathogenesis through modulation of the ECM. We have confirmed de novo synthesis of leptin within human aortic aneurysm wall. To directly study the effects of locally synthesized leptin on the arterial wall, we have used a new experimental approach that involves local periaortic application of leptin in ApoE -/mice, with serial ultrasound used to confirm progressive changes in aortic diameter. Subsequent gene expression changes and histological analyses shed light on early mechanisms that may underlie AAA formation in mice and potentially corollary aneurysmogenic processes in humans.
Materials and Methods
For a detailed description of leptin slow-release application manufacturing, kinetics of leptin slow-release, mouse plasma leptin antigen assay, human tissue mRNA extraction and real-time polymerase chain reaction, immunohistochemistry, and mouse tissue in situ zymography, see the online-only Data Supplement.
Human Tissue Collection
After obtaining informed consents and Institutional Review Board approval (Sheba Medical Center, Israel), samples of AAA wall (n=10) were collected during elective open AAA surgeries (3 had diabetes mellitus, 4 hypertension, 5 smokers, mean basal metabolic index [BMI] 27.5 kg/m 2 ). In addition, a small portion of aortic wall tissue with moderate atherosclerosis were sampled from nondilated abdominal aortas in age-matched patients (n=3) undergoing aortic bypass surgery and defined as controls (none had diabetes mellitus, 1 hypertension, 2 smokers; BMI was 26.4, 20.1, and 29.4 kg/m 2 ). Retroperitoneal fat was also sampled from those patients (n=3).
Periaortic Leptin Model in ApoE -/-Mice
Sixteen-week-old male ApoE-deficient mice (ApoE -/-, C57BL/6 background; Jackson Laboratory) underwent laparotomy for localized paravisceral periaortic application of slow-release film-based application, containing either 20 μg leptin (n=10) or none (n=10), at the paravisceral location ( Figure II in the online-only Data Supplement). For all studies, mice were maintained on a Western diet (60 kcal% fat, D12492; Research Diets, New Brunswick, NJ). During the follow-up period, serial Duplex/ultrasound examinations (Vevo 2100; VisualSonics Inc, Toronto, Ontario, Canada) were performed on days 0, 14, 21, 28, 35, and 42 by an independent examiner blinded to treatment. Those measurements provided a noninvasive longitudinal monitoring of aortic diameter at selected reference locations: juxtarenal (1 mm distal to the superior mesenteric artery), paravisceral (between the superior mesenteric artery and celiac trunk), and supraceliac (2 mm proximal to the celiac trunk). Ultrasound measurements of maximal aortic diameter were performed on cross-section axial views of the aorta during maximal aortic expansion, at end-systole. Animals were phlebotomized using a retro-orbital approach on days 0, 7, 14, 21, and 28. After euthanasia on day 45, aortic segments were embedded in optimal cutting temperature compound for histology and immunohistochemical analysis. Aortas collected from additional 24 ApoE -/mice receiving a similar periaortic application of leptin or placebo (10 euthanized on postoperative day [POD]-5 and 14 on POD-28]) were used for mRNA analysis.
Periaortic Leptin Model in ApoE -/-Mice Receiving Ang II
Sixteen-week-old male ApoE -/mice were randomized to receive local periaortic leptin slow-release in gel format (≈1.25 µg/µL in a total volume of 30-50 µL per animal; n=16) or a placebo gel with a similar volume (n=16). Notably, a gel packaging format of the leptin slow-release application was selected to achieve better contact with the aortic wall via its engulfment, although it is likely that only a fraction of the leptin diffused to the aortic wall. Each mouse subsequently underwent (within the same anesthesia) a subcutaneous implantation of Alzet osmotic minipump (model 2004; Durect Corp, Cupertino, CA) for continuous infusion of Ang II (1000 ng/kg per min). All mice received Western diet (60 kcal%) after surgery. The abdominal and arch segments of the aorta were weekly examined by high-resolution ultrasound, and aortic diameter was measured in axial view at endsystole phase using M-mode cine image sequences. The mice were euthanized after 28 days. Cross-sectional slides of formalin fixed aorta at different levels were assessed by microscopic morphometry and immunohistochemistry for MMP-9 and Mac-3 antigen. MMP-9 immunoreactive positive intracellular signals were quantitated within the full width of the intima/media.
Statistical Analysis
All results are reported as means±SEM. Statistical analyses were performed by 1-way ANOVA followed by Holm-Sidak/Tukey Pairwise Comparisons or Student t test/Mann-Whiteney Rank Sum Test (Sigma Stat 3.5; Systat Software, Chicago, IL). Probability value ≤0.05 was considered statistically significant.
Results

Leptin Is Expressed in Surgical Samples From Human AAA Wall
Samples of human AAA wall typically exhibited moderate to severe medial degradation recognized by a depletion of α-SMC actin with collagen replacement and marked loss of elastin fibers ( Figure 1A-1C ). Near the luminal surface, areas of atheromatous material and organized thrombi were apparent. Leptin antigen ( Figure 1E , 1e) was expressed primarily in macrophages and to a lesser degree in SMCs, in particular, near inflamed media together with leptin receptor ( Figure 1F, 1f ). Macrophage infiltrates were prevalent in AAA media and adventitia ( Figure 1D ). Age-matched control samples of nondilated abdominal aorta showed preservation of the media, with rare infiltrating macrophages ( Figure I in the online-only Data Supplement). The expression of leptin antigen was absent or weak, whereas leptin receptor was absent.
Parallel AAA tissue revealed a significant increase in leptin transcript in 9 of 10 samples, whereas ObR mRNA was increased in 4 samples ( Figure 1G ). Mean leptin mRNA in AAA wall samples was increased 8-fold compared with transcript levels in nondilated aortic samples. Adipose tissue samples (retroperitoneal fat from control subjects), used as a positive control, exhibited the highest levels of leptin and ObR mRNA (an increase of ≈80-fold compared with control nondilated aortas for leptin). Transcriptional analysis of ECM degrading enzymes MMP-9 and -12 demonstrated a 30-fold increase in mRNA expression of both genes in AAA wall samples compared with nondilated control aortic samples ( Figure  1H ). Adipose tissue, again serving as a positive control, displayed a 200-fold increase for MMP-9 mRNA.
Leptin and ObR Are Not Increased in the Plasma of Patients With AAA
As systemic levels of leptin have been shown to be unrelated to the presence of AAA, 14 the elevated mRNA transcript in AAA wall samples must be a local event. To confirm this in our study, leptin antigen plasma levels in AAA patients (including those whose aortic wall was analyzed) were measured. Plasma leptin levels in AAA patients compared with levels in BMImatched patients awaiting carotid endarterectomy surgery for asymptomatic carotid stenosis were found to be within the same range; AAA patients showed a mean leptin level of 8.71±4.64 μg/mL (mean BMI 26.4±0.90), and asymptomatic carotid patients showed a mean leptin of 6.16±5.40 μg/mL (mean BMI 25.7±2.3). Comparing both groups showed no statistically significant difference (P=0.2). Thus, the induction of leptin synthesis in AAA wall occurs locally and is not reflected in systemic circulation.
Local Application of Leptin Accelerates Growth of Abdominal Aortic Diameter in ApoE -/-Mice
To test the relationship between locally synthesized leptin and AAA formation, we turned to a new model system in mice. A leptin slow-release application was developed, with the intention of being administered at the periaortic space, thereby simulating its local synthesis (see Materials and Methods in the online-only Data Supplement for detailed kinetic analysis). The leptin slow-release application was administered at the abdominal periaortic space of ApoE -/male mice. These mice received Western diet (60 kcal %) after surgery to achieve a proatherogenic and hypercholesterolemic background. All mice recovered uneventfully from surgery, resumed normal eating and drinking, and survived the scheduled in-life-phase of the study. Mice receiving periaortic leptin or placebo exhibited a similar pattern of weight gain throughout 45 day of follow-up (data not shown). Importantly, to verify that the local application of the slow-release leptin film resulted in only local elevation of leptin levels, systemic plasma leptin was determined in these mice, as well as ones that received twice as much leptin. All subjects showed no elevation in plasma leptin compared with placebo control, and all values were within the normal range ( Figure IIF in the online-only Data Supplement).
Serial high-resolution duplex ultrasound examinations performed in all mice at 3 reference locations in the abdominal aorta measured and recorded aortic diameter at the end-systolic phase (Figure 2A and 2B) . These measurements revealed an accelerated increase in maximal diameter (relative to day 0) in leptin-treated mice compared with placebo controls. The pattern of accelerated growth in aortic diameter was evident in the segment extending from the juxta-renal to the supraceliac aorta ( Figure 2C ). The mean aortic diameter in leptin-treated mice was 1.03 mm on day 0 and increased to 1.209 mm on day 28 (17% change). In contrast, placebo-treated mice exhibited aortic diameter of 0.935 mm on day 0 that remained unchanged by day 28. In the juxta-renal location, the difference in percent diameter change between leptin-and placebo-treated aortas reached statistical significance on day 35 (P=0.0005) and remained significant through day 42 (P=0.0126). In the paravisceral location, the difference was significant from day 28 (P=0.0001) and persisted through days 35 (P=0.0007) and 42 (P=0.0274). The supraceliac location exhibited the same pattern, with a significant difference by day 28 (P=0.0011), and persisting through days 35 (P=0.0275) and 42 (P=0.0006). Notably, the increase in aortic diameter recorded at the end-systolic phase represents the augmented distensibility of the aortic wall.
Periaortic Leptin Modulates mRNA Levels of TGF-β, MMP-9, and ObR in the Aorta
Total RNA was extracted individually from each aorta in leptin-treated and placebo-treated mice on POD-5 (5 per group) and on POD-28 (7 per group). Real-time polymerase chain reaction was used for mRNA analysis of 23 selected genes known to be modulated by leptin (Table in the onlineonly Data Supplement). In aortic samples collected at day 5, transforming growth factor (TGF)-β mRNA was suppressed by 1.9-fold (P=0.002), whereas MMP-9 was upregulated by 1.4-fold (P=0.047) in leptin-treated mice compared with placebo-treated mice ( Figure 3A) . Notably, mRNA for TGF-β receptors 1 and 2 and MMP-12 did not appear to be modulated by leptin on day 5 aortic samples. Analysis of aortic wall samples at POD-28 revealed upregulation of ObR (LepR) mRNA by 1.3-fold (P=0.034). 
Local Leptin Delivery in Mouse Aorta Promotes ECM Degeneration, Coinciding With MMP Upregulation and Macrophage Infiltration
Aortas from leptin-treated mice characteristically demonstrated localized degeneration of the medial ECM (Figure 4 ). This included fragmented elastic lamellas (blue arrow) and depleted smooth muscle α-actin (P=0.072). Aortic sections from mice treated with placebo as well as remote sections collected from the descending aorta in leptin-treated mice exhibited no medial structural changes. Furthermore, staining for MMP-9 and -12 antigens was markedly increased in areas of medial degeneration (P=0.027 and P<0.001, respectively) compared with placebo controls. Additionally, we found a significant increase in MAC-3-positive adventitial macrophage infiltration in leptin-treated aortas (P=0.052). Finally, in situ zymography for MMP-9 provided evidence for elastolytic activity in tissue from leptin-treated aortas harvested at 45 days ( Figure 5 ).
Periaortic Leptin Application in ApoE -/-Mice Simultaneously Receiving Ang II Augments Aortic Aneurysm Diameter
We next wanted to test the impact of locally applied leptin in the context of an established murine model of AAA formation. To this end, we chose to combine our experimental approach with the Ang II-induced aortic aneurysm model. All mice received Ang II infusion (1000 ng/kg per min) and were fed postoperatively with Western diet (60 kcal%). As described in previous reports, the basic Ang II model generates harsh conditions that cause high mortality from aortic aneurysm rupture among subjects. 13 In our hands, lethal rupture of the aortic arch aneurysms occurred in 50% of placebo-and 43% of leptin-treated ApoE -/-. Most fatalities (70%) occurred within 7 days after surgery ( Figure 6A ). Among mice that completed the 28-day scheduled survival with local leptin and systemic Ang II, we observed an increase in growth rate and final size of the resulting paravisceral aortic aneurysm compared with placebo-treated mice (P=0.069; Figure 6B and 6C). Aortic diameter assessment by ultrasound on day 28 correlated well with final histological morphometry (r=0.852; P=0.001, data not shown). Mean aortic diameter in leptin-treated mice was 1.12 mm on day 0 and increased to 1.78 mm by day 28 (58% change). Placebo-treated mice presented a mean aortic diameter of 1.17 mm on day 0 and 1.50 mm by day 28 (28% change). Notably, the increase in aortic diameter represents a local fixed augmentation of the vessel diameter that is related to the aneurysm formation. Leptin-treated mice exhibited increased MMP-9 immunologic staining ( Figure 6D; P=0.003 ), as well as increased macrophage clustering in the paravisceral aortic segment (data not shown). 
Discussion
We have found that leptin is locally synthesized in the aortic aneurysm wall of human subjects. To test the local effects of this synthesis, we used a novel method of leptin delivery in mice. This study demonstrates that leptin deployed at the perivascular space of the abdominal aorta induces local remodeling of the vessel wall media in ApoE -/mice. Notably, the dose of leptin that was used is much lower than those administered in previous murine experiments designed to test its systemic modulation. 29 The benign course of the experiment was not only within safe physiological boundaries but may also be simulating a naturally occurring process in the aortic wall with pathological impact. These observations suggest a causative link between local leptin availability and aortic wall degeneration. As the local application of leptin leads to changes in gene expression, these likely underlie, at least in part, its remodeling effects, through ECM synthesis and proteolysis. These processes may be regarded as early events that precede subsequent development of AAA. Furthermore, sustained periaortic leptin deployed with a powerful aneurysmogenic stimulus like systemic Ang II demonstrates the potential of leptin to augment aneurysm size, beyond the initial process of medial ECM degeneration.
The remodeling effect of leptin on the mouse abdominal aorta could be traced chronologically, because modulation of TGF-β and MMP-9 gene expression in the vessel wall was recorded as early as POD-5. Analysis of the mouse aorta on day 45 revealed local histological features of advanced ECM degeneration. These were exclusively found in the region adjacent to the deployed leptin and could account for the increased aortic distensibility that was demonstrated by ultrasonography. Proteolytic enzymes MMP-9 and -12, known to participate in ECM degradation, were both increased at 45 days after leptin treatment. We also found evidence for MMP-9related elastolytic activity associated with leptin delivery. Therefore, the results obtained from the mouse model were consistent with the mRNA findings in human AAA wall samples and corroborated previous reports on murine and human AAAs. 30, 31 Notably, MMP-9 and -12 mRNAs were also increased in human retroperitoneal adipose tissue, likely because of their synthesis by adipocytes 32 and infiltrating macrophages, respectively. This increase may be linked to adipose cell differentiation and leptin-induced angiogenesis. 33 Adventitial macrophage infiltration, a hallmark of murine and human AAA pathogenesis, 9, 24 was also found to be increased as shown by MAC-3 positive staining in leptin-treated mice. We assume that augmentation of MMP-12 antigen seen on day 45 originated mostly from locally recruited macrophages, although this antigen can also be increased merely by reduction of TGF-β levels per se as previously demonstrated. 34 The decrease in TGF-β mRNA levels by POD-5 suggests that its decline underlies the remodeling effects of leptin in our system. It is currently unclear to what degree these changes in mRNA abundance are reflected in TGF-β protein levels. However, this reduction is consistent with previous studies that suggest an important role for TGF-β in the pathogenesis of murine and human AAA. TGF-β affects both ECM synthesis and degradation, 35 therefore perturbation of its signaling may contribute to aortic aneurysms. Furthermore, mutations in human TGF-β receptor genes have been found to be associated with AAA formation. [36] [37] [38] Ang II, which plays a role in murine and human aortic aneurysm formation, 39 also augments TGF-β systemic levels. 40 These may promote AAA and thoracic aneurysms in ApoE -/mice and humans. 41, 42 On the contrary, mouse models that exclusively generate AAAs constitute a different pathological phenotype, characterized by the association between TGF-β suppression and aneurysm formation. These differences may stem from aneurysm location, and the pathology of ECM modulation may be related to the local (rather than systemic) expression of TGF-β in the vessel wall. This concept warrants further studies of in vivo TGF-β plasma levels. Notably, a large body of experimental and clinical data supports the notion that TGF-β preserves the integrity of the ECM. [43] [44] [45] In addition to early changes in TGF-β and MMP-9 mRNA levels observed in POD-5 aortas, our analysis detected a trend of modulation of a few other leptin-related genes. Although short of statistical significance, these genes may play a role in vessel wall remodeling and AAA formation. This applies to nuclear factor-κB, a signal transduction pathway for leptin, 46 Ang II type 1 receptor, whose availability is critical for Ang II aneurysmogenic effects, 47, 48 and also osteopontin, a remodeling hormone that participates in AAA formation. 49 Interestingly, the ObR (LepR) transcript, which was statistically not elevated in POD-5 leptin-treated aortas, was found to be significantly upregulated in POD-28 aortic samples. Further studies should be performed to validate that the local increase in ObR transcripts leads to elevated local protein production. It is, however, not surprising that leptin would induce the physiological conditions that are required for its continuous activity, through modulation of its own receptor, as has previously shown in the liver. 50 It is important to note that the leptin-induced changes in gene expression affecting the paravisceral aortic segment are likely an underestimation, because whole aortas were analyzed in our study, thus effectively diluting the affected cells. Nonetheless, the physiological validity of these changes is made clear by the ECM degeneration that resulted from the exposure to leptin in our system.
Our results clearly demonstrate that local application of leptin is sufficient to induce regional ECM degeneration. However, the synergistic effects of leptin with systemic Ang II suggest that leptin underlies progressive degeneration of the vessel wall beyond early medial ECM remodeling. Ang II plays a significant role in human AAA formation 40 and therefore is frequently used to generate AAA in ApoE -/mice. Relevant to our studies, there are multiple in vitro data in support of interaction between Ang II and leptin. For example, Ang II has been shown to induce leptin in rat cardiomyocytes 51 and also in human AAA-derived SMCs via Ang II type 1 receptor. 52 Leptin is also known to induce Ang II type 1 receptor, which may potentiate the impact of Ang II locally. Chymase, a proteolytic enzyme released from periadventitial mast cells on interaction with leptin, is known to convert Ang I to Ang II within the aortic wall. 53, 54 Furthermore, chymase also plays an important role in AAA formation in ApoE -/mice via MMP-9 activation. 55 Ang II and leptin are most probably interconnected via a paracrine loop, and potentiate each other at the vessel wall, and likely work synergistically in AAA formation in vivo.
Although here we show that leptin is sufficient to induce medial degeneration preceding AAA, the ability of obese leptin-deficient mice (Ob/Ob) to generate aortic aneurysms in response to Ang II infusion demonstrates that leptin alone does not underlie all cases of ECM destabilization. 56 This is not surprising, as any event that leads to vessel wall destabilization would be expected to contribute to AAA formation. It is therefore still an open question what intrinsic role leptin normally plays in aneurysms, or whether a local physiological predisposition is a prerequisite for the development of an arterial aneurysm. 57 However, the strong correlation we observe between local leptin induction and AAA in human patients and the causal link between them in mice leads us to support a conceptual model in which endogenous local induction of leptin normally contributes to aneurysm pathology. AAA formation in humans is a lengthy process, and one could speculate that repeated episodes of local leptin induction in the aorta analogous to our leptin slow-release system may occur over time. Progressive destabilization may render the vessel wall vulnerable to multiple systemic factors also involved in vascular degeneration throughout the course of human aging. Although in vivo mechanisms capable of inducing leptin in the vessel wall were beyond the scope of this study, we should consider a possible scenario in which leptin is locally induced by both systemic and local cytokines like tumor necrosis factor-α, as elicited by active inflammation or recurrent bacterial infections. 28 Interestingly, tumor necrosis factor-α is abundantly expressed in AAA wall, and an experimental mouse model has demonstrated its critical role in AAA genesis. 58, 59 Because our survey of modulated transcripts in response to leptin was not exhaustive, it is likely that additional functional genes in the aortic tissue are modulated in vivo. However, regardless of additional changes and the potential cause of leptin induction at the aortic wall, the conceptual model we propose here may have far reaching implications regarding potential therapies for AAA in humans. For instance, if local synthesis of leptin underlies AAA formation, local blocking of leptin may be more therapeutically advantageous than attempting to antagonize secondary systemic processes involved in the progression of the degenerative AAA process.
